Cancer-Killing virus joins forces with immunotherapy in new trial
Disease control
Recruiting now
This early-phase trial tests a cancer-killing virus (SVV-001) injected directly into tumors, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 36 adults with advanced neuroendocrine tumors that have worsened after standard treatment. The main goals are to find …
Phase: PHASE1 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC